Perth Roadshow, page-27

First 27 Last

Share
Profile

Follow
The Greenkeeper

1,003 Posts.

34

16/05/17

13:40

Post #: 24717519
Share

Originally posted by meerkat ↑

1. I don't believe the market will ever take to the idea that it's OK for a company to withhold the names of its clients. Traditionally a big part of what makes a company's sp strong is the quality of its clients - keeping such things secret undermines that possibility, so it's not in IAM's interest. Furthermore, if IAM is allowed to be secretive about such things then how many other companies would follow suit? The ASX IMO would be asking for trouble to allow such a thing. And think about the sham companies in the ASX (for that is what many are) who just pay their ASX dues and cruise along as lifestyle companies, they would use such secrecy tactics to maintain their continuing existence.

2. IAM can't avoid making earnings projections at some stage, unless they are going to say they are never going to give earnings guidance - again it's not in IAM's long term interest.

If IAM's clients insist on confidentiality then so be it, IAM should have nothing to do with them. If they have issues it's their problem not IAM's. Maybe everything should be 'portalised' to eliminate the necessity of having contracts with single big clients using some kind of distributed user system which though reportable didn't have the same impact on major clients? That's for IAM to work out, but allowing IAM to have secret clients is not the way to go.

Expand

could delay mentioning client names be an option? say 12 months of silence?

IAM Price at posting: 4.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

There are more pages in this discussion • 27 more messages in this thread...

First 27 Last

Add CF1 (ASX) to my watchlist

(20min delay)
Last 2.2¢		Change 0.001(4.76%)		Mkt cap ! $12.49M

Open	High	Low	Value	Volume
2.0¢	2.2¢	2.0¢	$114.6K	5.281M

Buyers (Bids)

No.	Vol.	Price($)
1	200000	2.2¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	500000	1

View Market Depth

No.	Vol.	Price($)
1	200000	0.022
1	103307	0.020
1	688535	0.019
1	345696	0.018
2	1200000	0.017

Price($)	Vol.	No.
0.040	500000	1
0.044	500000	1
0.060	17225	1
0.090	6007	1
0.140	500000	1

Last trade - 15.32pm 09/07/2024 (20 minute delay)

CF1 (ASX) Chart

Perth Roadshow, page-27

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Perth Roadshow, page-27

Top Stories

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News